BBIOHealthcare · BiotechnologyThe 22 Wall Street analysts covering BridgeBio Pharma, Inc. hold a median 12-month price target of $110 — +51.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 68 of 100 as at 12 Sept 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores BridgeBio Pharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (93): The share price has been relatively steady.
Issuance (13): The company has been issuing shares or taking on financing, diluting existing holders.
Size (12): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on BBIO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +51.8% from it.
Of the 20 most recent actions, 7 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $120 |
| 2 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $120 |
| 1 Sept 2026 | Mizuho | Maintains | Outperform | — |
| 1 Sept 2026 | Mizuho | Maintains | Outperform | $96 → $110 |
| 12 Aug 2026 | Canaccord Genuity | Maintains | Buy | — |
| 12 Aug 2026 | Canaccord Genuity | Maintains | Buy | $104 → $106 |
| 12 Aug 2026 | JP Morgan | Maintains | Overweight | — |
| 12 Aug 2026 | JP Morgan | Maintains | Overweight | $100 → $111 |
| 12 Aug 2026 | Truist Securities | Maintains | Buy | $102 → $107 |
| 12 Aug 2026 | Truist Securities | Maintains | Buy | — |
| 11 Aug 2026 | B of A Securities | Maintains | Buy | — |
| 11 Aug 2026 | B of A Securities | Maintains | Buy | $101 → $104 |
| 11 Aug 2026 | Morgan Stanley | Maintains | Overweight | — |
| 11 Aug 2026 | Morgan Stanley | Maintains | Overweight | $98 → $97 |
| 11 Aug 2026 | Piper Sandler | Maintains | Overweight | $111 → $115 |
| 11 Aug 2026 | Piper Sandler | Maintains | Overweight | — |
| 11 Aug 2026 | TD Cowen | Maintains | Buy | — |
| 11 Aug 2026 | TD Cowen | Maintains | Buy | $95 → $110 |
| 11 Aug 2026 | Wells Fargo | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BBIO appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, BridgeBio Pharma, Inc. returned +37.8% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 96% of US stocks
Cheaper than 9% of US stocks
Cheaper than 97% of US stocks
Cheaper than 92% of US stocks
Higher than 94% of US stocks
Higher than 86% of US stocks
Higher than 98% of US stocks
Higher than 18% of US stocks
Higher than 6% of US stocks
Higher than 90% of US stocks
Higher than 16% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
BridgeBio Pharma, Inc. has a market value of $14.2B and an enterprise value of $16.8B.
Revenue in the twelve months to 30 June 2026: $713.1M. The latest quarter grew 120.4% year on year.
Net income over the same four quarters: −$702.0M, a −98.5% net margin.
Diluted earnings per share, trailing twelve months: $−3.57.
Free cash flow in the twelve months to 30 June 2026: −$437.8M.
BridgeBio Pharma, Inc. spent $228.8M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: −19.2×; forward P/E: 2637.1× — the forward figure prices analyst consensus estimates, not reported earnings.
BridgeBio Pharma, Inc. employs 999 people — $714K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own BridgeBio Pharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
BridgeBio Pharma, Inc. presented at the 12th Annual Cantor Fitzgerald Global Healthcare Conference, and a transcript of the presentation was published by Seeking Alpha.
Why it matters — BBIO watchers would care because the conference transcript provides a record of what the company communicated to investors and analysts at the event.
BridgeBio Pharma's management has guided higher peak sales for Attruby, which continues to beat sales estimates. The company also saw competitor setbacks and new data on Attruby's kidney benefits and hospital day reduction, further strengthening its commercial outlook, despite past share sell-offs after positive catalysts.
Why it matters — A BridgeBio watcher would care because the higher Attruby peak sales guidance, combined with competitor setbacks and supportive clinical data, points to an improving commercial trajectory for the company.
BridgeBio Pharma presented at the Wells Fargo 21st Annual Healthcare Conference, and a transcript of its presentation was published. The company participated in the event as part of its engagement with investors and industry analysts.
Why it matters — A BBIO watcher would care because the company's remarks at the conference can provide insight into its strategy, pipeline, and outlook directly from management.
BridgeBio Pharma reported earnings 30 days ago, and its stock has declined 10.7% since that report. The article examines whether the stock can rebound in the near term.
Why it matters — A BBIO watcher would care because the post-earnings decline reflects recent market sentiment about the company's performance and near-term prospects.
BridgeBio reported results from the Phase 3 PROPEL 3 trial of oral infigratinib in children with achondroplasia, showing favorable trends against placebo in exploratory endpoints such as sleep apnea and otitis media events over 52 weeks, beyond growth benefits.
Why it matters — The data expands the potential clinical value of infigratinib beyond growth, which could be relevant to BridgeBio's achondroplasia development program.
The 22 Wall Street analysts covering BridgeBio Pharma, Inc. have a median 12-month price target of $110, with estimates ranging from $80 to $157. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 22 analysts covering BridgeBio Pharma, Inc., 19 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BridgeBio Pharma, Inc. 68 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, BridgeBio Pharma, Inc. ranks 68 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (93 of 100).
No one can know that. What the data says: the median 12-month target from 22 analysts implies +51.8% from the last close, and Ticker Nerd's factor model ranks BridgeBio Pharma, Inc. 68 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering BridgeBio Pharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BBIO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $80 to $157 over the next 12 months.
BridgeBio Pharma, Inc. returned +37.8% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
BridgeBio Pharma Inc. is a commercial-stage biopharmaceutical company focused on developing medicines for genetic conditions.
The most recent item we track (Seeking Alpha, 10 Sept 2026): "BridgeBio Pharma, Inc. (BBIO) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript". BridgeBio Pharma, Inc. presented at the 12th Annual Cantor Fitzgerald Global Healthcare Conference, and a transcript of the presentation was published by Seeking Alpha.
BridgeBio Pharma Inc. is a commercial-stage biopharmaceutical company focused on developing medicines for genetic conditions. BridgeBio Pharma Inc. discovers, develops, tests, and delivers therapies aimed at patients with rare and inherited diseases, with programs spanning cardiology, endocrinology, muscle disease, gene therapy, and selected oncology. The company’s current portfolio includes approved medicines such as Attruby for transthyretin amyloid cardiomyopathy and Nulibry for a rare metabolic disorder, alongside a pipeline of investigational treatments for additional genetic disorders. BridgeBio Pharma Inc. works with academic and industry partners to advance precision medicines and bring targeted treatment options to underserved patient groups. Headquartered in Palo Alto, California, BridgeBio Pharma Inc. plays a significant role in the genetic-disease biopharmaceutical market through its mix of commercial products and late-stage development programs.
CEO Dr. Neil Kumar Ph.D. · 999 employees · United States · https://bridgebio.com
